The New England Journal of Medicine published an editorial yesterday on its website rising the doubts of the safety of the drug Vytorin and its cancer link. It concludes that “physicians and patients are unfortunately left for now with uncertainty about the efficacy and safety of the drug”.
Vytorin is a combination of 2 drugs : a statin called simvastatin and ezetimibe, a new drug for lowering cholesterol . Vytorin is one of the best-selling drugs in the world and heavily prescribed by doctors although there is little evidence that ezetimibe offers the same benefits as stains.
The SEAS trials of Vytorin, conducted by reserachers in Norway found that Vytorin lowered the average levels of “bad” LDL cholesterol but not the aortic valve disease. It also found unexpectedly more cancer cases among patients taking Vytorin than the placebo.
This has prompted the analysis of the ezetimibe trials by Oxford researchers. When the results from all trials were combined, they did not find an increased incidence of cancer and they concluded that there is "no credible evidence of any side effect of ezetimibe on cancer risk". However, they suggest that “follow-up of longer duration will permit the balance of risks and benefits to be determined more reliably.”
Source: Both articles are published online on Sept 2 at the NEJM website ( will appear in Sept 25 issue of the journal)
No comments:
Post a Comment